Summary

Overview
The Global Digital Biomarkers Market reached US$ 4.16 Billion in 2024 and is expected to reach US$ 26.69 Billion by 2033, growing at a CAGR of 22.7% during the forecast period 2025-2033.
Digital biomarkers are objective, quantifiable data collected through digital devices like wearables, smartphones, sensors, and mobile applications. They are crucial for monitoring health conditions, tracking disease progression, and evaluating treatment responses in real-time. These biomarkers capture physiological metrics like heart rate, blood pressure, glucose levels, sleep patterns, activity levels, and cognitive performance. They can also analyze voice and speech patterns for neurological conditions, assess gait and movement for mobility disorders, and monitor eye movements and facial expressions for mental health changes.
Market Dynamics: Drivers & Restraints
Growing Adoption of Wearable Devices and Mobile Health Technologies
The global digital biomarkers market is driven by the increasing use of wearable devices and mobile health technologies. With chronic diseases like cardiovascular disorders, diabetes, and neurological conditions, continuous health monitoring is crucial. Wearable devices like smartwatches, fitness trackers, and biosensors collect real-time data, aiding in early disease detection, personalized treatment, and improved patient outcomes. This growth is driving digital biomarkers in clinical and non-clinical settings.
For instance, in December 2024, ElectronRx, a leading digital medicine and biomarker company, launched purpleDx, a cardiopulmonary assessment app designed to meet medical device standards at CES 2025. The app allows chronic respiratory disease patients to monitor digital biomarkers of lung function at home, providing real-time data for clinicians to customize treatment plans and improve patient outcomes. purpleDx was developed in collaboration with respiratory clinics and the European pulmonary hypertension association, aiming to detect, monitor, and treat pulmonary diseases like asthma, chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary hypertension.
Data Security and Privacy Concerns
Digital biomarkers face significant data privacy and security challenges due to the collection and analysis of sensitive health data through connected devices. Compliance with strict regulations like GDPR in Europe and HIPAA in the U.S. adds complexity to the market, potentially limiting user adoption and creating barriers for healthcare providers and organizations integrating digital biomarkers into routine care.
Segment Analysis
The global Digital Biomarkers market is segmented based on, System Component, Application, End User and Region.
System Component:
Wearable Devices segment is expected to dominate the Digital Biomarkers market share
The wearble devices segment holds a major portion of the Digital Biomarkers market share and is expected to continue to hold a significant portion of the Digital Biomarkers market share during the forecast period.
Wearable devices, such as smartwatches, fitness trackers, and biosensors, are crucial in the Global Digital Biomarkers Market for real-time monitoring of physiological and behavioral data. They track key health metrics, enabling informed decision-making by patients and healthcare providers. Wearables are essential for disease management, early detection, and personalized healthcare, providing objective data for conditions like cardiovascular diseases, diabetes, and neurological disorders.
End User:-
Pharmaceutical Companies segment is the fastest-growing segment in Digital Biomarkers market share
The pharmaceutical companies segment is the fastest-growing segment in the Digital Biomarkers market share and is expected to hold the market share over the forecast period.
Pharmaceutical companies are utilizing digital biomarkers to accelerate drug development, improve clinical trials, and optimize patient outcomes. These biomarkers enable real-time monitoring of trial participants, enabling more comprehensive data on disease progression, treatment efficacy, and patient adherence. This helps identify potential adverse effects earlier and aids in personalized treatments. Digital biomarkers also aid in regulatory processes by providing accurate data for FDA and EMA approvals. As a result, pharmaceutical companies are embracing digital biomarkers to drive innovation, improve patient care, and streamline the drug development process.
For instance, in November 2024, Neuron23, a biotechnology company, has partnered with Roche to use a digital biomarker developed by Roche Information Solutions as the primary endpoint in the global Phase 2 NEULARK clinical trial of NEU-411, a potent inhibitor of LRRK2 in early-stage Parkinson's disease, as the primary endpoint.
Geographical Analysis
North America is expected to hold a significant position in the Digital Biomarkers market share
North America holds a substantial position in the Digital Biomarkers market and is expected to hold most of the market share due to high healthcare expenditure and advanced infrastructure are driving the digital biomarkers market. The US and Canada invest heavily in healthcare technology, enabling the adoption of innovative solutions like digital biomarkers for chronic disease management and clinical trials. The growing prevalence of chronic diseases like diabetes, cardiovascular conditions, and mental health disorders has increased the demand for continuous health monitoring. The widespread adoption of smartphones, wearable devices, and telemedicine further enhances the integration of digital biomarkers in everyday healthcare.
For instance, in May 2024, the Digital Biomarker Summit USA, held in Tarrytown, NY in May 2024, discussed the use of digital biomarkers in clinical trials, the integration of wearable devices with AI, and the impact of digital phenotyping on observational research.
Europe is growing at the fastest pace in the Digital Biomarkers market
Europe holds the fastest pace in the Digital Biomarkers market and is expected to hold most of the market share is due to the country's focus on healthcare innovation and regulatory support. Strong regulatory frameworks like the European Medicines Agency and GDPR ensure patient safety and data security, encouraging the use of digital biomarkers in clinical trials and healthcare applications. The region is also investing in preventive healthcare and personalized medicine, with high adoption of digital health solutions like wearables and mobile health apps, and increasing consumer demand for continuous healthcare monitoring.
Competitive Landscape
The major global players in the digital biomarkers market include Koneksa Health, Altoida Inc, Empatica Inc, Evidation Health, Inc., ActiGraph LLC, Quartet Health, IXICO plc, Vivo Sense, Aural Analytic, Neurotrack Technologies, Inc and among others.
Key Developments
• In February 2024, Biofourmis, a global leader in digital biomarker development and decentralized clinical trial solutions, has formed four new partnerships with top pharmaceutical companies, leveraging their expertise in digital biomarker innovation and strengthening clinical trial programs across the US, Europe, Asia-Pacific, and MEA.
• In March 2024, Indivi and Biogen have partnered to develop digital biomarkers for Parkinson's disease. The collaboration will use the Konectom platform, managed in the Phase 2b LUMA study, which evaluates the effectiveness and safety of BIIB122 for early-stage Parkinson's patients. The study is in partnership with Denali Therapeutics Inc.
Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
The global Digital Biomarkers market report delivers a detailed analysis with 61 key tables, more than 59 visually impactful figures, and 210 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2024
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.

• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.

• System Component & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.

• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.

• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.

• Supply Chain: Distribution and Supply Chain Managers.

• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.

• Academic & Research: Academic Institutions.

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by System Component
3.2. Snippet by Application
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing Adoption of Wearable Devices and Mobile Health Technologies
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Data Security and Privacy Concerns
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Strategic Insights and Industry Outlook
5.1. Market Leaders and Pioneers
5.1.1. Emerging Pioneers and Prominent Players
5.1.2. Established leaders with largest selling Brand
5.1.3. Market leaders with established Product
5.2. CXO Perspectives
5.3. Latest Developments and Breakthroughs
5.4. Case Studies/Ongoing Research
5.5. Regulatory and Reimbursement Landscape
5.5.1. North America
5.5.2. Europe
5.5.3. Asia Pacific
5.5.4. Latin America
5.5.5. Middle East & Africa
5.6. Porter’s Five Force Analysis
5.7. Supply Chain Analysis
5.8. Patent Analysis
5.9. SWOT Analysis
5.10. Unmet Needs and Gaps
5.11. Recommended Strategies for Market Entry and Expansion
5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
5.13. Pricing Analysis and Price Dynamics
5.14. Key Opinion Leaders
6. By System Component
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By System Component
6.1.2. Market Attractiveness Index, By System Component
6.2. Wearable Devices*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Mobile Applications
6.4. Sensors
6.5. Digital Platforms
6.6. Data Integration & Analytics Platforms
6.7. Others
7. By Application
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.1.2. Market Attractiveness Index, By Application
7.2. Cardiovascular Diseases*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Neurological Disorders
7.4. Respiratory Disorders
7.5. Metabolic Disorders
7.6. Gastrointestinal Disorders
7.7. Others
8. By End User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.1.2. Market Attractiveness Index, By End User
8.2. Pharmaceutical Companies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Healthcare Providers
8.4. Payers
8.5. Academic & Research Institutions
8.6. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By System Component
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By System Component
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By System Component
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By System Component
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By System Component
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
Key Market Players
11.1. Koneksa Health*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue’s
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals etc.
11.1.5. SWOT Analysis
11.2. Biobeat Technologies Ltd.
11.3. Empatica Inc.
11.4. Evidation Health, Inc.
11.5. ActiGraph LLC
11.6. mHealth Technologies
11.7. Quartet Health
11.8. Fitabase (Small Steps Labs LLC)
11.9. Spire Health
11.10. Mindstrong Health
* Similar data will be provided for each market player.
Emerging Market Players
11.11. Koneksa Health*
11.11.1. Pipeline Products Description
11.11.2. Product Key Performance Indicators (KPIs)
11.11.3. Key Activities
11.11.4. Market Entry Timelines
11.11.5. Product Penetration Rate
11.11.6. Sales Estimation and Projections
11.12. Biobeat Technologies Ltd.
11.13. Empatica Inc.
11.14. Evidation Health, Inc.
* Similar data will be provided for each market player.
LIST NOT EXHAUSTIVE
12. Appendix
12.1 About Us and Services
12.2 Contact Us